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Abstract 
Purpose: To synthesise a new series of 5-substituted-1,3,4-Oxadiazol-2yl-4-(morpholin-4yl 
sulfonyl)benzyl sulfide and evaluate their antibacterial activity. 
Methods: Different organic acids were converted consecutively into corresponding esters, hydrazides 
and 5-substituted-1,3,4-Oxadiazol-2-thiols (4a-e). The targets, 6a-e were synthesized by stirring 4a-e 
with 4-(4-(bromomethyl)phenylsulfonyl) morpholine (5) in the presence of N,N-dimethylformamide 
(DMF) and sodium hydride (NaH). All the structures were elucidated by modern spectroscopic 
techniques and screened against bacteria using standard procedure and ciprofloxacin drug as positive 
control. 
Results: The yield of the synthesized compounds (4a-e and 6a-e) were moderate (65 - 90 %). 
Compounds 6a-e had antibacterial activity against Pseudomonas aeruginosa, Bacillis subtilis and 
Staphylococcus aureus while some had activity against the other bacteria used. One of the compounds, 
6b, exhibited significant activity against all the bacterial strains, i.e., S. typhi (-), E. coli (-), K. 
pneumoniae (-), P. aeruginosa (-), B. subtilis (+) and S. aureus (+) with MIC (μM) values of 11.01 ± 
0.31, 15.37 ± 3.33, 16.11 ± 1.14, 9.70 ± 1.96, 10.01 ± 2.70 and 9.15 ± 0.29, respectively. However, 
none of the compounds had any inhibitory activity against any bacteria as high as that of ciprofloxacin. 
Conclusion: Five new compounds with antibacterial activities have been synthesized. Their potential 
as therapeutic agents is, however, yet to be evaluated.  
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Organic chemists are interested in designing and 
synthesizing fresh and therapeutically active 
compounds, useful to alleviate different disorders 
and diseases. Scientists are facing a serious 
problem of increased resistance of microbes 
against the traditional antimicrobial drugs and so 
are interested in developing new biologically 
active compounds with excellent therapeutic 
activity. Oxadiazole is a class of heterocyclic 
organic compounds that is known because of its 
magnificent therapeutic potential. Thousands of 
oxadiazole and their derivatives have been 
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synthesized and evaluated for different 
antimicrobial and enzyme inhibition activities. 
Oxadiazole possesses splendid anti-
inflammatory [1,2], fungicidal [3], insecticidal [4], 
herbicidal [5], antibacterial [6], antitumor [7], 
antitubercular [8], antiviral, anticonvulsant and 
analgesic activities [9]. Furthermore, morpholine 
and its analogues are important in pharmaceutics 
due to their great enzyme inhibition potential, 
antimicrobial and antioxidant activity [10,11].  
 
Synthesis of new morpholine containing 
compounds is the area of interest for the 
pharmacists because therapeutically potent 
compounds are needed to cure different 
malfunctions and diseases [12]. This current 
work (an extension of previous work, [13-15]) 
aimed to synthesize poly-functional compounds 
having 1,3,4-oxadiaozloe and sulfa morpholine 
moiety together in an individual molecule. It was 
expected that 2,5-disubstituted 1,3,4-oxadiazole 
ring along with the potential morpholine moiety 
will boost up the antibacterial activity of the 
molecule and hence the synthesized compounds 





All the chemicals and analytical grade solvents 
were purchased through local suppliers. Melting 
points were taken on Griffin and George melting 
point apparatus by open capillary tube method. 
TLC plate F256 20 x 20 cm coated with silica gel 
was used to detect the purity of synthesized 
compounds, developed by different ratios of n-
Hexane and EtOAc as solvent system. With the 
help of KBr pellet method, IR spectrum was 
recorded by using Jasco-320-A 
spectrophotometer. 1H-NMR spectra were 
recorded on Bruker spectrometers at frequency 
of 400 MHz, taken in deuterated chloroform, 
indicating chemical shifts value in ppm taking 
TMS as reference standard. 
 
Synthesis of ethyl esters of different 
substituted carboxylic acids (2a-e)  
 
The organic acids [(5 g, Piperonylic acid (1a); 
3,4-(Methylenedioxy)cinnamic acid (1b); Nicotinic 
acid (1c); 2-naphthyl acetic acid (1d); 3,5-dinitro-
2-methyl benzoic acid (1e)]  were taken in 250 
mL round bottom flask and dissolved in 20 mL 
ethanol along with 2.5 mL concentrated H2SO4. 
The mixture was refluxed for 2-3 h. TLC was 
used to monitor the reaction completion by using 
n-hexane and EtOAc as solvent system. On 
completion, reaction contents were shifted to a 
separating funnel containing distilled H2O (20 
mL). The contents were neutralized using 
concentrated Na2CO3 solution (15 %). Diethyl 
ether was added to the separating funnel 
followed by shaking, allowed to separate into two 
layers and the ethyl esters (2a-e) were recovered 
following by evaporating the diethyl ether. 
 
Synthesis of different hydrazides (3a-e) 
 
The ethyl esters (25 mmol, 3a-e) were taken in 
250 mL RB flask and dissolved in methanol (60 
mL). Hydrazine hydrate (80 %, 0.05-0.07 mol) 
was introduced to the reaction flask along with 
stirring for 4-5 h at room temperature. Some of 
the hydrazides were formed at room temperature 
while some esters got altered on refluxing with 
constant stirring. Completion of reaction was 
monitored by TLC using n-hexane and EtOAc as 
solvent system. On completion, cold distilled H2O 
was added to obtain the precipitates. Precipitates 
of hydrazides (3a-e) were filtered, washed with 





The hydrazides (0.01 mol, 3a-e) were taken in 
250 mL RB flask, dissolved in ethanol and CS2 
(0.01 mol) was added followed by the addition of 
KOH (0.03 mol) to provide basic media. The 
mixture was refluxed for 5-6 h and reaction 
progress was monitored by TLC. The reaction 
completion was confirmed by TLC and the 
reaction mixture was acidified (pH = 2) to remove 
un-reacted hydrazides in the form of salts and 
also to convert thiol group of oxadiazole into 
acidic form. Precipitates (4a-d) were filtered, 
washed with H2O and dried. Precipitates were re-
crystallized by methanol. 
 
Synthesis of 4-(4-(bromomethyl)phenyl 
sulfonyl)morpholine (5) 
 
Morpholine (0.005 mol) was added into a round 
bottom flask containing basic aqueous solution 
with a pH 9-10. Equimolar 4-(bromomethyl) 
benzenesulfonyl chloride was introduced to the 
reaction flask with constant stirring under 
dynamic pH control. The completion of reaction 
was monitored via TLC utilizing different ratios of 
n-hexane and EtOAc. On completion, reaction 
mixture was acidified (pH = 2) to obtain the 
product (5). Precipitates were filtered, washed 
with water and dried.  
 
Synthesis of 5-substitued-1,3,4-Oxadiazole-2-
yl 4-(morpholin-4yl sulfonyl)benzyl sulfide 
(6a-e) 
 
5-substituted-1,3,4-oxadiazole-2-thiols (0.1 g, 4a-
e) were taken in 50 mL RB flask and dissolved in 
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dimethylformamide. On complete dissolution, 2 
mg NaH was added and stirred for half an hour. 
The electrophile, 4-(4-(bromomethyl)phenyl 
sulfonyl) morpholine (5) was added to the 
reaction mixture, and stirring was continued for 
further 1-2 h. TLC was used to check the 
reaction completion by using n-hexane and 
EtOAc as a solvent system. On completion, cold 
distilled water was added to get the precipitates 
which were then filtered, washed with H2O and 
dried. The pathway for the synthesis of 6a-e is 
provided in scheme 1 while the different 5-
substituted aryl/aralky groups of synthesized 
compounds are shown in Table 1. 
 
In summary, the synthesis was carried out in 
different steps. First, the different organic acids 
(1a-e) were converted into subsequent ethyl 
esters (2a-e) by refluxing in concentrated H2SO4 
and ethanol for 2-3 h. Second, the ethyl esters 
(2a-e) were consequently transformed into 
hydrazides (3a-e) by refluxing with hydrazine 
hydrate (80 %) using ethanol as a solvent for 4-5 
h. Third, the hydrazides (3a-e) were cyclized to 
5-substituted-1,3,4-oxadiazoles-2-thiols (4a-e) by 
refluxing for 5-6 h with CS2 in the presence of 
KOH. The products were acquired by acidifying 
the reaction mixture. The electrophile 5 was 






















































Scheme-1: Outline for the synthesis of 5-substituted-1,3,4-Oxadiazole-2-yl 4-(morpholin-4-ylsulfonyl)benzyl 
sulfide. Reagents & conditions: (I) H2SO4/EtOH/refluxing for 2-3 h (II) N2H4/MeOH/stirring for 4-5 h (III) 
CS2/KOH/EtOH/refluxing for 5-6 h (IV) 4-bromomethylbenzenesulfonyl chloride/H2O/5 % Na2CO3 soln./stirring for 
1 h (V) DMF/NaH/stirring for 2-3 h 
 
Table-1: Different 5-substituted aryl/aralkyl groups of synthesized compounds 
 





































Aziz-ur-Rehman et al 
Trop J Pharm Res, November 2015; 14(11): 2050  
 
bromomethylbenzenesulfonyl chloride in the 
presence basic aqueous media. Fourth, these 5-
substituted-1,3,4-Oxadiazoles-2-thiols (4a-e) 
were treated with 4-(4-(bromomethyl) 
phenylsulfonyl)morpholine (5) in the presence of 
dimethylformamide as solvent and sodium 
hydride as base. The final products (6a-e) were 
collected by the addition of cold water. The 
structures of all the synthesized compounds 
were established by 1H-NMR, IR and mass 
spectral data as illustrated in experimental 
section.  
 
Antibacterial activity assay 
 
The antibacterial activity assay was processed 
on sterile 96-wells microplates under sterile 
conditions. Synthesized compounds were 
screened against four Gram-negative and two 
Gram-positive bacteria as previously reported 
[13-15]. Briefly, the test organisms were 
maintained on stock culture agar medium.  Each 
test sample (in suitable solvent and appropriate 
dilution) was pipetted into each well (20 µg/well). 
Freshly maintained overnight bacterial culture 
(180 µL), after dilution with fresh nutrient broth, 
was poured into each well which was then 
incubated at 37 oC for 16-24 h under cover of a 
microplate. Absorbance was measured at 540 
nm using microplate reader, before and after 
incubation and the difference was noted as an 
index of bacterial growth using ciprofloxacin as 
reference standard. Percentage inhibition of each 
bacteria was calculated and the minimum 
inhibitory concentration (MIC) was measured 
using suitable dilutions (5-30 µg/ well) of each 
compound.  
 
Statistical analysis  
 
All the calculations for MIC values were made 
after performing the experiments in triplicate. The 
triplicate calculated values were analyzed 
statistically through Microsoft Excel 2010 with CL 








(morpholin-4yl sulfonyl)benzyl sulfide (6a) 
 
Light pink amorphous solid; Yield: 88 %; M.P: 
140-142 oC; molecular formula: C20H19N3O6S2; 
Mol. Wt: 461; IR (KBr, cm-1) vmax: 3439 (C-H 
stretching of benzene ring), 2929 (C-H stretching 
–CH2), 1623 & 1610 (C=N stretching of 
Oxadiazole ring), 1463 (Ar-C=C aromatic 
stretching band), 1408 (-SO2- stretching), 1331 & 
1143 (C-O-C bond stretching); 1H-NMR (400 
MHz, CDCl3, δ / ppm); 7.56 (d, J = 8.0 Hz, 2H, H-
2'' & H-6''), 7.53 (d, J = 8.4 Hz, 2H, H-3'' & H-5''), 
7.34 (d, J = 8.0 Hz, 1H, H-6'), 7.24 (d, J = 2.0 Hz, 
1H, H-4'), 6.76 (d, J = 8.4 Hz, 1H, H-7'), 5.89 (s, 
2H, CH2-2'),  4.38 (s, 2H, CH2-7''), 3.57 (t, J = 4.4 
Hz, 4H, CH2-2'''& CH2-6'''), 2.81 (t, J = 4.4 Hz, 
4H, CH2-3'''& CH2-5'''); EIMS (m/z): 461 [M]+, 311 
[M-C4H8NO3S]+, 271[C11H13NO3S]+, 240 
[C11H14NO3S]+, 221 [M-C11H14NO3S]+, 189 [M-
C11H14NO3S]+, 149 [M-C12H14N3O3S2]+, 147 [M-





sulfonyl)benzyl sulfide (6b) 
 
Light green amorphous solid; Yield: 66 %; M.P: 
156-158 oC; molecular formula: C22H21N3O6S2; 
Mol. Wt: 487; IR (KBr, cm-1) vmax: 3438 (C-H 
stretching of benzene ring), 2927 (C-H stretching 
–CH2), 1622 & 1611 (C=N stretching of 
Oxadiazole ring), 1462 (Ar-C=C aromatic 
stretching band), 1407 (-SO2- stretching), 1330 & 
1142 (C-O-C bond stretching); 1H-NMR (300 
MHz, CDCl3, δ / ppm); 7.63 (d, J = 8.0 Hz, 2H, H-
2'' & H-6''), 7.54 (d, J = 8.4 Hz, 2H, H-3'' & H-5''), 
7.38 (d, J = 8.0 Hz, 1H, H-6'), 7.29 (d, J = 16.5 
Hz, 1H, H-9'), 6.93 (d, J = 16.5 Hz, 1H, H-8'), 
6.88 (s, 1H, H-4'), 6.70 (d, J = 8.4 Hz, 1H, H-7'), 
5.90 (s, 2H, CH2-2'),  4.43 (s, 2H, CH2-7''), 3.63 
(t, J = 4.2 Hz, 4H, CH2-2'''& CH2-6'''), 2.90 (t, J = 
4.2 Hz, 4H, CH2-3'''& CH2-5'''); EIMS (m/z): 487 
[M]+, 337 [M-C4H8NO3S]+, 271[C11H13NO3S]+, 
240 [C11H14NO3S]+, 247 [M-C11H14NO3S]+, 215 
[M-C11H14NO3S]+, 175 [M-C12H14N3O3S2]+, 173 




4yl sulfonyl)benzyl sulfide (6c) 
 
Off white amorphous solid; Yield: 77 %; M.P: 
161-163 oC; molecular formula: C18H18N4O4S2; 
Mol. Wt: 418; IR (KBr, cm-1) vmax: 3437 (C-H 
stretching of benzene ring), 2925 (C-H stretching 
–CH2), 1621 & 1613 (C=N stretching of 
Oxadiazole ring), 1463 (Ar-C=C aromatic 
stretching band), 1405 (-SO2- stretching), 1331 & 
1143 (C-O-C bond stretching); 1H-NMR (400 
MHz, CDCl3, δ / ppm); 8.71 (s, 1H, H-2'), 7.91 
(br.s, 1H, H-4'), 7.75 (d, J = 7.6 Hz, 1H, H-6'), 
7.67 (d, J = 8.0 Hz, 2H, H-2'' & H-6''), 7.63 (d, J = 
8.8 Hz, 2H, H-3'' & H-5''),7.58 (t, J = 8.4 Hz, 1H, 
H-5'), 4.54 (s, 2H, CH2-7'')  3.63 (t, J = 4.4 Hz, 
4H, CH2-2'''& CH2-6'''), 2.92 (t, J = 4.8 Hz, 4H, 
CH2-3'''& CH2-5'''); EIMS (m/z): 418 [M]+, 268 [M-
C4H8NO3S]+, 271[C11H13NO3S]+, 240 
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[C11H14NO3S]+, 178 [M-C11H14NO3S]+, 146 [M-
C11H14NO3S]+, 106 [M-C12H14N3O3S2]+, 104 [M-




4-(morpholin-4yl sulfonyl)benzyl sulfide (6d) 
 
Off white amorphous solid; Yield: 64 %; M.P: 
190-192 oC; molecular formula: C24H23N3O4S2; 
Mol. Wt: 481; IR (KBr, cm-1) vmax: 3447 (C-H 
stretching of benzene ring), 2923 (C-H stretching 
–CH2), 1620 & 1611 (C=N stretching of 
Oxadiazole ring), 1461 (Ar-C=C aromatic 
stretching band), 1404 (-SO2- stretching), 1329 & 
1141 (C-O-C bond stretching); 1H-NMR (400 
MHz, CDCl3, δ / ppm); 8.00 (d, J = 8.0 Hz, 1H, H-
4'), 7.80 (d, J = 7.6 Hz, 1H, H-8'), 7.77(d, J = 6.8 
Hz, 1H, H-5'), 7.51 (d, J = 8.4 Hz, 1H, H-3'), 7.49 
(s, 1H, H-1'),  7.48-7.44 (m, 2H, H-6' & H-7'), 
7.38 (d, J = 8.0 Hz, 2H, H-2'' & H-6''), 7.36 (d, J = 
8.0 Hz, 2H, H-3'' & H-5''), 4.53 (s, 2H, CH2-2'), 
4.29 (s, 2H, CH2-7''), 3.64 (t, J = 4.4 Hz, 4H, 
CH2-2'''& CH2-6'''), 2.87 (t, J = 4.8 Hz, 4H, CH2-
3'''& CH2-5'''); EIMS (m/z): 481 [M]+, 331 [M-
C4H8NO3S]+, 271[C11H13NO3S]+, 240 
[C11H14NO3S]+, 241 [M-C11H14NO3S]+, 209 [M-
C11H14NO3S]+, 169 [M-C12H14N3O3S2]+, 167 [M-




2yl-4-(morpholin-4yl sulfonyl)benzyl sulfide 
(6e) 
 
Yellow amorphous solid; Yield: 79 %; M.P: 247-
249 oC; molecular formula: C20H19N5O8S2; Mol. 
Wt: 521; IR (KBr, cm-1) vmax: 3441 (C-H 
stretching of benzene ring), 2933 (C-H stretching 
–CH2), 1624 & 1607 (C=N stretching of 
Oxadiazole ring), 1465 (Ar-C=C aromatic 
stretching band), 1409 (-SO2- stretching), 1333 & 
1145 (C-O-C bond stretching); 1H-NMR (300 
MHz, CDCl3, δ / ppm); 7.65 (d, J = 8.1 Hz, 2H, H-
2'' & H-6''), 7.60 (d, J = 8.1 Hz, 2H, H-3'' & H-5''), 
7.16 (d, J = 2.7 Hz, 1H, H-4'), 7.08 (d, J = 2.7 Hz, 
1H, H-6'), 4.47 (s, 2H, CH2-7''), 3.65 (t, J = 
4.5Hz, 4H, CH2-2'''& CH2-6'''), 2.88 (t, J = 4.8 Hz, 
4H, CH2-3'''& CH2-5'''); EIMS (m/z): 521 [M]+, 371 
[M-C4H8NO3S]+, 271[C11H13NO3S]+, 240 
[C11H14NO3S]+, 281 [M-C11H14NO3S]+, 249 [M-
C11H14NO3S]+, 209 [M-C12H14N3O3S2]+, 207 [M-





The percentage inhibition of each bacteria and 
the MICs are presented in Tables 2 and 3, 
respectively. All five compounds synthesized had 
antibacterial activity against P. aeruginosa, B. 
subtilis and S. aureus while the growth of S. 
typhi, E. coli and K. pneumoniae was inhibited by 
four, one and two of the compounds, 
respectively. All the compounds, however, had 
lower levels of inhibition and higher MIC against 





The intention of the presented research work 
was to synthesize biologically active molecules. 
We have synthesized some new 2,5-
disubstituted 1,3,4-oxadiazole molecules and to 
find out the anti-bacterial activity of all the 
synthesized molecules. We synthesized 5-
substituted-1,3,4-oxadiazol-2yl-4-(morpholin-4yl 
sulfonyl)benzyl sulfide (6a-e) derivaives in good 
yields having significant antibacterial activities. 
Compound 6a was synthesized as a light pink 
amorphous solid having yield 88 % and melting 
point 140 - 142 oC. In the IR spectrum, the 
characteristic peaks appeared at 3439 cm-1, 
1632 cm-1, 1443 cm-1 and 1408 cm-1 which were 
corresponding to C-H stretching, C=N stretching, 
C=C stretching and stretching of sulfonyl group 
respectively. The molecular formula 
C20H19N3O6S2 was established by HR-MS 
showing molecular ion [M]+ peak at m/z 461.516 
(cald for C20H19N3O6S2 461.513).  In the EI-MS 
spectrum, four distinct peaks appeared at m/z 
149, 147, 121 and 86 which pointed out the 
presence of 1,3-benzodioxol-5-yl carbonyl cation, 
1,3-benzodioxol-5-yl cyanide cation, 1,3-
benzodioxole cation and morpholine cation 
fragments respectively in the molecule. 
 
Table 2: Inhibition (%) of selected bacterial strains by five 5-substituted-1,3,4-Oxadiazole-2-yl 4-(morpholin-4-





S. typhi (-) E.coli (-) K.pneumonae (-) P.aeruginosa (-) B. subtilis (+) S. aureus (+) 
6a 56.33±1.44 - - 75.35±0.06 60.36±1.31 54.55±2.95 
6b 75.00±0.33 56.91±4.12 55.59±1.14 84.59±0.71 82.20±0.54 77.85±3.45 
6c 50.94±0.39 - - 76.94±0.12 61.37±0.42 61.70±0.80 
6d - - - 59.71±3.03 50.24±1.43 51.75±1.65 
6e 55.22±1.78 - 53.59±1.14 50.32±2.08 60.50±3.40 57.06±0.12 
Ciprofloxacin 91.14±0.84 88.94±1.21 90.65±1.29 90.36±1.86 91.33±1.99 91.87±2.51 
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Table 3: MIC of five 5-substituted-1,3,4-Oxadiazole-2-yl 4-(morpholin-4-ylsulfonyl)benzyl sulfides (6a-e) against 





S. typhi (-) E. coli (-) K. pneumonae(-) P. aeroginosa (-) B. subtilis (+) S. aureus (+) 
6a 16.34±3.00 - - 12.39±1.45 12.52±0.10 17.28±4.07 
6b 11.01±0.31 15.37±3.33 16.11±1.14 9.70±1.96 10.01±2.70 9.15±0.29 
6c 18.49±0.38 - - 13.16±3.45 12.50±2.40 13.99±0.86 
6d - - - 16.79±4.55 19.87±2.20 17.16±0.57 
6e 16.56±2.23 - 16.27±1.14 18.86±2.10 11.49±1.64 17.58±3.21 
Ciprofloxacin 8.26±0.92 9.14±0.28 8.92±0.41 8.56±1.18 9.11±1.30 8.48±1.43 
Minimum inhibitory concentration (MIC) was measured with suitable dilutions of test samples (5-30 µg/ well) and 
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Figure 1: Mass fragmentation pattern of 5-(1,3-benzodioxol-5-yl)-1,3,4-oxadiazol-2yl-4-(morpholin-4yl 
sulfonyl)benzyl sulfide (6a) 
 
The 1H-NMR spectrum showed four signals at δ 
7.34 (d, J = 8.0 Hz, 1H, H-6'), 7.24 (d, J = 2.0 Hz, 
1H, H-4'), 6.76 (d, J = 8.4 Hz, 1H, H-7') and 5.89 
(s, 2H, CH2-2') in the downfield region owing to 
protons of 1,3-benzodioxole moiety attached to 
the 5-position of oxadiazole ring. 
 
Two signals were resonated at δ 7.56 (d, J = 8.0 
Hz, 2H, H-2'' & H-6'') and 7.53 (d, J = 8.4 Hz, 2H, 
H-3'' & H-5''), due to higher coupling constant 
and each signal with integration of two protons, 
indicating the presence of para substituted 
aromatic ring. The two signals emerging at δ 
9.54 (s, 1H, CON-H) and 4.36 (s, 2H, CH2-2) 
which depicted the presence of acetamide group 
in the molecule. In the aliphatic region of the 
spectrum, two triplet were appeared at δ 3.57 (t, 
J = 4.4 Hz, 4H, CH2-2'''& CH2-6''') and 2.81 (t, J = 
4.4 Hz, 4H, CH2-3'''& CH2-5''') each with 
integration of four protons, showed the presence 
of morpholine ring and a methylene signal was 
appeared at 4.38 (s, 2H, CH2-7'').  
 
The mass fragmentation pattern of 6a was also 
clearly sketched in Fig 1. All the above signals 
collectively established the structure of 
compound 6a and named as 5-(1,3-benzodioxol-
5-yl)-1,3,4-oxadiazol-2yl-4-(morpholin-4yl 
sulfonyl)benzyl sulfide. Similarly, the structures of 
all the other synthesized compounds were 
elucidated with the help of above mentioned 




Some of the synthesized compounds were 
moderate inhibitors of three bacterial strains 
employed in this study. One of the compounds, 
6b, exhibited significant activity against all the 
bacterial strains i.e. S. typhi (-), E. coli (-), K. 
pneumoniae (-), P. aeruginosa (-), B. subtilis (+) 
and S. aureus (+) with MIC (μM) values of 11.01 
± 0.31, 15.37 ± 3.33, 16.11 ± 1.14, 9.70 ± 1.96, 
10.01 ± 2.70 and 9.15 ± 0.29 respectively. This 
compound was found to be more active because 
of the presence of 1,3-benzodioxol-5-yl ethenyl 
Aziz-ur-Rehman et al 
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group attached to the oxadiazole ring present in 
the molecule. Against Pseudomonas aeruginosa, 
the order of activity of the compounds were 
6b>6c>6a>6d>6e from the highest activity to 
lowest activity but lower antibacterial activity than 
the standard compound used in this assay. 
Overall the activity revealed by the synthesized 
compounds was good as supported by their MIC 
values. Such kind of compounds can further be 
exploited and their derivatives could be 





New compounds (6a-e) with antibacterial activity 
have been synthesized. One of the compounds 
inhibited the growth of four Gram negative (S. 
typhi, E. coli, K. pneumoniae, P. aeruginosa) and 
two Gram positive (B. subtilis and S. aureus) 
bacterial strains. Thus, the compounds are 
potential lead molecules in the search for potent 
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